AU2003236787B2 - Use of alkylphosphocholines for the preventative treatment of protozoan diseases - Google Patents
Use of alkylphosphocholines for the preventative treatment of protozoan diseases Download PDFInfo
- Publication number
- AU2003236787B2 AU2003236787B2 AU2003236787A AU2003236787A AU2003236787B2 AU 2003236787 B2 AU2003236787 B2 AU 2003236787B2 AU 2003236787 A AU2003236787 A AU 2003236787A AU 2003236787 A AU2003236787 A AU 2003236787A AU 2003236787 B2 AU2003236787 B2 AU 2003236787B2
- Authority
- AU
- Australia
- Prior art keywords
- active ingredient
- use according
- miltefosine
- leishmaniasis
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 title claims description 26
- 201000010099 disease Diseases 0.000 title claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 18
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims description 85
- 229960003775 miltefosine Drugs 0.000 claims description 85
- 239000004480 active ingredient Substances 0.000 claims description 36
- 208000004554 Leishmaniasis Diseases 0.000 claims description 31
- 230000003449 preventive effect Effects 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 16
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 claims description 16
- 230000003474 anti-emetic effect Effects 0.000 claims description 14
- 239000002111 antiemetic agent Substances 0.000 claims description 14
- 229950010632 perifosine Drugs 0.000 claims description 14
- 230000001142 anti-diarrhea Effects 0.000 claims description 13
- 229940124537 antidiarrhoeal agent Drugs 0.000 claims description 13
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 238000012423 maintenance Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 claims description 4
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 230000009278 visceral effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000945 filler Substances 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 239000007938 effervescent tablet Substances 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000007786 electrostatic charging Methods 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229960001567 sodium stibogluconate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960003687 alizapride Drugs 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Chemical class 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Chemical class 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 208000000498 diffuse cutaneous leishmaniasis Diseases 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229940016777 miltefosine 50 mg Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- -1 pentavalent antimony compounds sodium stibogluconate Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10203195A DE10203195A1 (de) | 2002-01-25 | 2002-01-25 | Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen |
| DE10203195.9 | 2002-01-25 | ||
| PCT/EP2003/000072 WO2003061669A1 (de) | 2002-01-25 | 2003-01-07 | Verwendung von alkylphosphocholinen in der präventivbehandlung von protozoenerkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003236787A1 AU2003236787A1 (en) | 2003-09-18 |
| AU2003236787B2 true AU2003236787B2 (en) | 2007-03-22 |
Family
ID=7713213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003236787A Expired AU2003236787B2 (en) | 2002-01-25 | 2003-01-07 | Use of alkylphosphocholines for the preventative treatment of protozoan diseases |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1467742A1 (https=) |
| JP (1) | JP2005515244A (https=) |
| CN (1) | CN1622811A (https=) |
| AR (1) | AR038224A1 (https=) |
| AU (1) | AU2003236787B2 (https=) |
| BR (1) | BR0307021A (https=) |
| CA (1) | CA2470185A1 (https=) |
| CO (1) | CO5601024A2 (https=) |
| DE (1) | DE10203195A1 (https=) |
| IL (2) | IL162492A0 (https=) |
| MX (1) | MXPA04007193A (https=) |
| NZ (1) | NZ548040A (https=) |
| PE (1) | PE20030732A1 (https=) |
| TW (1) | TWI339582B (https=) |
| WO (1) | WO2003061669A1 (https=) |
| ZA (1) | ZA200404690B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT501545B1 (de) * | 2005-02-23 | 2007-10-15 | Obwaller Andreas Dr | Reinigungsmittel für kontaktlinsen |
| CA2632449A1 (en) * | 2005-12-19 | 2007-06-28 | Aeterna Zentaris Gmbh | Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| EP1800684A1 (en) * | 2005-12-20 | 2007-06-27 | Zentaris GmbH | Novel alkyl phospholipid derivatives and uses thereof |
| CN104473941A (zh) * | 2014-12-20 | 2015-04-01 | 长沙佰顺生物科技有限公司 | 一种含有米替福新的药物制剂及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037289A1 (en) * | 1998-01-22 | 1999-07-29 | Asta Medica Ag | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4132345A1 (de) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Ether-lysolecithine und alkylphosphocholine in liposomen |
| DE4132344A1 (de) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis |
| BR9306040A (pt) * | 1992-03-06 | 1997-11-18 | Statens Seruminstitut | Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias |
| DE10020812C2 (de) * | 2000-04-20 | 2003-06-26 | Robert Koch Inst | Verwendung von Naphthindazol-4,9-chinonen als Antiparasitika |
| AU2002232400A1 (en) * | 2000-11-06 | 2002-05-15 | U.S. Army Medical Research And Materiel Command | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
-
2002
- 2002-01-25 DE DE10203195A patent/DE10203195A1/de not_active Withdrawn
-
2003
- 2003-01-07 IL IL16249203A patent/IL162492A0/xx unknown
- 2003-01-07 CN CNA038027062A patent/CN1622811A/zh active Pending
- 2003-01-07 CA CA002470185A patent/CA2470185A1/en not_active Abandoned
- 2003-01-07 EP EP03731619A patent/EP1467742A1/de not_active Ceased
- 2003-01-07 JP JP2003561613A patent/JP2005515244A/ja active Pending
- 2003-01-07 AU AU2003236787A patent/AU2003236787B2/en not_active Expired
- 2003-01-07 MX MXPA04007193A patent/MXPA04007193A/es active IP Right Grant
- 2003-01-07 WO PCT/EP2003/000072 patent/WO2003061669A1/de not_active Ceased
- 2003-01-07 NZ NZ548040A patent/NZ548040A/en not_active IP Right Cessation
- 2003-01-07 BR BR0307021-2A patent/BR0307021A/pt not_active Application Discontinuation
- 2003-01-13 TW TW092100614A patent/TWI339582B/zh not_active IP Right Cessation
- 2003-01-20 PE PE2003000061A patent/PE20030732A1/es not_active Application Discontinuation
- 2003-01-24 AR ARP030100214A patent/AR038224A1/es unknown
-
2004
- 2004-06-14 ZA ZA200404690A patent/ZA200404690B/en unknown
- 2004-06-14 IL IL162492A patent/IL162492A/en active IP Right Grant
- 2004-07-23 CO CO04070642A patent/CO5601024A2/es not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037289A1 (en) * | 1998-01-22 | 1999-07-29 | Asta Medica Ag | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007193A (es) | 2004-10-29 |
| NZ548040A (en) | 2007-06-29 |
| TW200302103A (en) | 2003-08-01 |
| BR0307021A (pt) | 2004-11-03 |
| AR038224A1 (es) | 2005-01-05 |
| JP2005515244A (ja) | 2005-05-26 |
| IL162492A0 (en) | 2005-11-20 |
| TWI339582B (en) | 2011-04-01 |
| IL162492A (en) | 2009-12-24 |
| EP1467742A1 (de) | 2004-10-20 |
| ZA200404690B (en) | 2004-09-27 |
| CA2470185A1 (en) | 2003-07-31 |
| PE20030732A1 (es) | 2003-09-27 |
| CN1622811A (zh) | 2005-06-01 |
| WO2003061669A1 (de) | 2003-07-31 |
| DE10203195A1 (de) | 2003-08-07 |
| CO5601024A2 (es) | 2006-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0306060B1 (en) | Pharmaceutical products providing enhanced analgesia | |
| EP0500823B1 (en) | Antimalarial compositions | |
| HK1000312B (en) | Antimalarial compositions | |
| CN100413492C (zh) | 口服给药治疗利什曼病的含有米替福星的固体药物组合物 | |
| JP2859318B2 (ja) | イノシトールトリホスフェートを含有する骨疾患に対する医薬 | |
| AU2003236787B2 (en) | Use of alkylphosphocholines for the preventative treatment of protozoan diseases | |
| US7887817B2 (en) | Process for preventing protozoal diseases | |
| GLUECK | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis | |
| US20130022673A1 (en) | Enhancement of magnesium uptake in mammals | |
| EP0813873B1 (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| EP2968185A1 (en) | Soft gel encapsulation | |
| CZ198999A3 (cs) | Nové terapeutické použití derivátu thienycyklohexylaminu | |
| HK1077217A (en) | Use of alkylphosphocholines for the preventative treatment of protozoan diseases | |
| Jokanovic et al. | Epidemiological studies of anticholinesterase pesticide poisoning in Serbia | |
| NO334701B1 (no) | Fremgangsmåte for å reagere alkaloider og anvendelse av reaksjonsprodukter i fremstillingen av medikamenter | |
| US4501737A (en) | Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat myodystrophia | |
| EP2413934B1 (en) | Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response | |
| JP2005515244A5 (https=) | ||
| CA2555406A1 (en) | Improved therapy using a combination of raloxifene and alendronate | |
| RU2174836C1 (ru) | Фармацевтическая композиция, обладающая анальгезирующим действием | |
| JP2007502811A (ja) | 肥満の予防用の医薬組成物の製剤におけるコリパーゼ−リパーゼ阻害剤の使用 | |
| ITMI991996A1 (it) | Composizioni per la somministrazione orale utili al trattamento di patologie di origine allergica | |
| WO1997006801A1 (en) | Composition containing mefenamic acid in association with codeine | |
| JPH0152364B2 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |